Making Cancer Screening More Accurate,
Earlier And Easier!
Laboratory for Advanced Medicine & Health Group (LAMH) is an AI-driven cancer screening and early diagnosis innovation company founded by international business leaders, top scientists and authoritative doctors with the concept of "making cancer screening more accurate, earlier and easier". LAMH was founded by international business leaders, top scientists and authoritative doctors with the concept of "making cancer screening more accurate, earlier and easier", and has raised over RMB 1 billion since its inception. As a global leader in early screening and diagnosis of cancer, LAMH has collaborated with many top cancer centers, universities and their affiliated hospitals, published relevant research results in top international journals such as Nature, Science, Cell and its sub-journals, PNAS, and established a full product pipeline for early screening and diagnosis of liver cancer, intestinal cancer, lung cancer and pan-cancer. LAMH is committed to providing a full lifecycle service with the help of AI-driven technology, combined with genomics and clinical medicine theories.
LAMH, an independent entity in China, is headquartered in the central business district of Pazhou, Guangzhou, with a R&D and registration center in Beijing Economic and Technological Development Zone, and a Southern and Northern Medical Laboratory (ICL) meeting PCR and NGS standards in Guangzhou Biological Island and Beijing Yizhuang, respectively. There is an IVD GMP factory in Guangzhou Science City that has passed the NMPA system assessment,Helio Genomics is a U.S. independent entity headquartered in Irvine, California, with CLIA - and CAP-certified central laboratories in Indiana.
Making cancer screening
more accurate earlier and easier
Technology-driven global leader
in early cancer screening
Mr. Zeyue Zhang has a rich background in Business, clinical medicine and biotechnology in the gene industry; He has management experience in start-up companies, multinational enterprises, well-known private enterprises and state-owned enterprises. He has worked in well-known domestic gene companies such as BGI, BoA, Roche and Novartis, as well as the sales department of well-known multinational pharmaceutical companies.
Bachelor of Medicine, Southern Medical University;
Executive Master of Business Administration (EMBA) from China Europe International Business School (CEIBS).
Dr. Shu Li is a successful entrepreneur in the biomedical field. He served as senior vice president of Conexant Systems, vice president and general manager of Honeywell Commercial Spare Parts, and held senior management positions in Motorola and Intel. Dr. Li Shu is a member of the Advisory Board of the University of California, Irvine (Business School), and has also served as a faculty member at the University of Arizona. He holds 6 US and international patents.
Bachelor of Automatic Control from Huazhong University of Science and Technology;
Degree in Electrical Engineering from the University of Illinois at Urbana-Champaign;
PhD in Applied Science from Harvard University.